Amid tough market conditions, Medivir AB CEO Niklas Prager is "convinced" that a sale of its Nordic Brands portfolio – operating as BioPhausia AB – to Karo Pharma "is the best way to maximize the value for our shareholders." He had been considering a separate listing on First North Premium, NASDAQ's European market for smaller, growing companies. (Also see "Medivir Plans For A Post-Simeprevir Future" - Scrip, 31 August, 2016.)
The SEK908m ($101m) cash and debt free sale to Karo Pharma means the commercial unit "can continue its positive development...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
